Reference is made to the stock exchange announcement made on6 June 2023 regardingNordic Nanovector ASA's ("Nordic Nanovector ") contemplated acquisition of all the issued and outstanding shares in Thor Medical AS (the "Transaction"), and the stock exchange announcement on 28 June regarding the approval of the Transaction by the Company's annual general meeting. The conditions for the consummation of the Transaction have now been fulfilled, and the Transaction has been successfully completed. As a result of the Transaction, the Company has acquired 100% of the shares of Thor Medical AS, i.e. the entire share capital on a fully diluted basis, against issuance of 116,769,503 new shares to the former shareholders of Thor Medical AS. Upon registration of the share capital increase pertaining to the issuance of new shares, the Company's new share capital will beNOK 46,707,801.20 divided by 233,539,006 shares, each of par valueNOK 0.20 . Furter, as a consequence of the Transaction, the Articles ofAssociation of the Company has been amended, including the change of the company name to Thor Medical ASA, and the provision relating to the purpose of the Company. The Company will also change its ticker to "TRMED". Additionally, Brede Ellingsæter has assumed the position as CFO of the Company. ContactsLudvik Sandnes , chairman of the board of directors +47 907 43 017 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source